Alex Martinko
Senior Director - Antibody Engineering & Design Cartography Biosciences
Dr. Alexander Martinko is Senior Director of Antibody Engineering and Design at Cartography Biosciences. A specialist in therapeutic antibody technologies, he previously co‑founded Soteria Biotherapeutics and led protein engineering efforts there. His doctoral work at UCSF under Dr. Jim Wells focused on proteomics and target discovery in RAS‑driven cancers. Dr. Martinko also contributed to educational innovation through the Next‑gen Educhem project.
Seminars
Wednesday 24th June 2026
Panel Discussion: Translating Mechanistic Insights into Effector Durability through Mitigating T-Cell Exhaustion
12:30 pm
- Analyzing whether mass changes in peripheral T-cell capacity serve as a predictive biomarker for clinical response r a signature of therapeutic failure
- Identifying points where TCEs fail to maintain sustained cytotoxic pressure and harnessing these insights to inform the timing of TCE administration
- Understanding how chronic antigen exposure under TCE stimulation drives effector dysfunction and how these findings can be used to engineer more resilient T-cell therapies
Wednesday 24th June 2026
Leveraging Single-Cell Sequencing to Identify Highly Precise Single and Combination T-Cell Engager Targets
12:00 pm
- Highlighting the central challenge in solid tumor T-cell engagers: identifying clean targets with high tumor specificity
- Cartography’s ATLAS platform: applying single-cell RNA sequencing to map tumor antigen expression and identify tumor-restricted antigens with broad patient coverage
- Discovery and advancement of CBI-1214, a T-cell engager targeting LY6G6D, a highly tumor-restricted colorectal cancer antigen entering the clinic in early 2026
- Extending this framework to multi-specific and AND-gated T-cell engagers through the SUMMIT platform, enabling identification of target pairs that further enhance therapeutic index
